PharmaBlock (stock code: 300725. SZSE), a global, fully integrated CRDMO company focusing on innovative chemistry and low-carbon manufacturing, is pleased to announce the appointment of Dr. Dezhi Sha as Senior Vice President of Process Technology and Manufacturing.

Dr. Sha brings a wealth of knowledge, experience and leadership in process R&D, manufacturing, operations, and project management covering preclinical, clinical and commercial stages to the role. Before joining PharmaBlock, Dr. Sha spent his entire career at Irix Pharmaceutical and Patheon, which later became part of ThermoFisher, served in various roles, including Process Section Head, VP of Process Technology and Site General Manager. During his 25 remarkable years tenure there, Dr. Sha successfully executed and managed hundreds of challenging API Process R&D, Analytical R&D, and manufacturing projects, advanced a dozen new APIs from toxicity batch to commercial launch. As Site Head, Dr. Sha oversaw numerous quality audits, including FDA inspections and PAIs, many times without any 483s.

In his new role at PharmaBlock, Dr. Sha will be responsible for developing the Process R&D teams in the US and China, providing strategic advisory leadership for all aspects of CDMO Business, especially in tech transfer and manufacturing operations. “Dr. Sha will be an important addition to our CDMO business development, ” says Dr. Minmin Yang, President of PharmaBlock, “his outstanding leadership and technical experience will be invaluable as we pursue our strategy to bring sustainable solution to Pharmaceutical industry.”